HAEM5:Langerhans cell histiocytosis - Revision history

Richard.Glen at 18:38, 3 February 2026

2026-02-03T18:38:09Z

Richard.Glen: Removed redirect to STBT5:Langerhans cell histiocytosis

2026-02-03T18:36:20Z

Removed redirect to STBT5:Langerhans cell histiocytosis

← Older revision		Revision as of 13:36, 3 February 2026
Line 1:		Line 1:
	~~#REDIRECT~~[[~~STBT5~~:~~Langerhans cell histiocytosis~~]]		y:HAEM5]]\n[[Category:DISEASE]]\n[[Category:Diseases L]]"}}}

Richard.Glen: Changed redirect target from CNS5:Langerhans cell histiocytosis to STBT5:Langerhans cell histiocytosis

2026-02-03T18:30:27Z

Changed redirect target from CNS5:Langerhans cell histiocytosis to STBT5:Langerhans cell histiocytosis

← Older revision		Revision as of 13:30, 3 February 2026
Line 1:		Line 1:
	#REDIRECT[[~~CNS5~~:Langerhans cell histiocytosis]]		#REDIRECT[[STBT5:Langerhans cell histiocytosis]]

Richard.Glen: Redirected page to CNS5:Langerhans cell histiocytosis

2026-02-03T18:30:26Z

Redirected page to CNS5:Langerhans cell histiocytosis

Show changes

Bailey.Glen at 17:19, 3 July 2025

2025-07-03T17:19:20Z

← Older revision		Revision as of 12:19, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:38, 25 May 2025

2025-05-25T21:38:50Z

← Older revision		Revision as of 16:38, 25 May 2025
Line 136:		Line 136:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 191:		Line 191:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 226:		Line 226:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 274:		Line 274:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:15, 25 May 2025

2025-05-25T20:15:07Z

← Older revision		Revision as of 15:15, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Langerhans cell granulomatosis; histiocytosis X; eosinophilic granuloma (solitary lesions); Hand–Schüller–Christian disease (multifocal); Letterer–Siwe disease (disseminated or visceral involvement)
	\|}		\|}

Bailey.Glen at 17:38, 24 March 2025

2025-03-24T17:38:50Z

← Older revision		Revision as of 12:38, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Langerhans cell histiocytosis}}		{{DISPLAYTITLE:Langerhans cell histiocytosis}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland		Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen at 18:08, 13 February 2025

2025-02-13T18:08:55Z

← Older revision		Revision as of 13:08, 13 February 2025
Line 190:		Line 190:
	\|}		\|}
	==Characteristic Chromosomal or Other Global Mutational Patterns==		==Characteristic Chromosomal or Other Global Mutational Patterns==
			Put your text here and fill in the table <span style="color:#0070C0">(I''nstructions: Included in this category are alterations such as hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis; microsatellite instability; homologous recombination deficiency; mutational signature pattern; etc. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
	~~Recurrent chromosomal abnormalities have not been described~~ in the ~~context~~ of ~~Langerhans cell histiocytosis~~.

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chromosomal Pattern		!Chromosomal Pattern
	!~~Diagnostic Significance (Yes~~, No or ~~Unknown~~)		!Molecular Pathogenesis
	!Prognostic Significance ~~(Yes~~, ~~No or Unknown)~~		!'''Prevalence -'''
	!~~Therapeutic~~ Significance (Yes, No ~~or Unknown~~)		'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
	!Notes		!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
			!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
			!'''Clinical Relevance Details/Other Notes'''
	\|-		\|-
			\|<span class="blue-text">EXAMPLE:</span>
			Co-deletion of 1p and 18q
			\|<span class="blue-text">EXAMPLE:</span> See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
			\|<span class="blue-text">EXAMPLE:</span> Common (Oligodendroglioma)
			\|<span class="blue-text">EXAMPLE:</span> D, P
			\|
			\|
			\|-
			\|<span class="blue-text">EXAMPLE:</span>
			Microsatellite instability - hypermutated
			\|
			\|<span class="blue-text">EXAMPLE:</span> Common (Endometrial carcinoma)
			\|<span class="blue-text">EXAMPLE:</span> P, T
			\|
			\|
			\|-
			\|
	\|		\|
	\|		\|

Bailey.Glen at 18:07, 13 February 2025

2025-02-13T18:07:31Z

← Older revision		Revision as of 13:07, 13 February 2025
Line 137:		Line 137:
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==
			Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 146:		Line 145:
	!'''Clinical Relevance Details/Other Notes'''		!'''Clinical Relevance Details/Other Notes'''
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>7		\|<span class="blue-text">EXAMPLE:</span>
			7
	\|<span class="blue-text">EXAMPLE:</span> Loss		\|<span class="blue-text">EXAMPLE:</span> Loss
	\|<span class="blue-text">EXAMPLE:</span>chr7		\|<span class="blue-text">EXAMPLE:</span>
	\|<span class="blue-text">EXAMPLE:</span>Unknown		chr7
			\|<span class="blue-text">EXAMPLE:</span>
			Unknown
	\|<span class="blue-text">EXAMPLE:</span> D, P		\|<span class="blue-text">EXAMPLE:</span> D, P
	\|<span class="blue-text">EXAMPLE:</span> No		\|<span class="blue-text">EXAMPLE:</span> No
	\|<span class="blue-text">EXAMPLE:</span>Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).		\|<span class="blue-text">EXAMPLE:</span>
			Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>8		\|<span class="blue-text">EXAMPLE:</span>
			8
	\|<span class="blue-text">EXAMPLE:</span> Gain		\|<span class="blue-text">EXAMPLE:</span> Gain
	\|<span class="blue-text">EXAMPLE:</span>chr8		\|<span class="blue-text">EXAMPLE:</span>
	\|<span class="blue-text">EXAMPLE:</span>Unknown		chr8
			\|<span class="blue-text">EXAMPLE:</span>
			Unknown
	\|<span class="blue-text">EXAMPLE:</span> D, P		\|<span class="blue-text">EXAMPLE:</span> D, P
	\|		\|
	\|<span class="blue-text">EXAMPLE:</span>Common recurrent secondary finding for t(8;21) (add references).		\|<span class="blue-text">EXAMPLE:</span>
			Common recurrent secondary finding for t(8;21) (add references).
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>17		\|<span class="blue-text">EXAMPLE:</span>
			17
	\|<span class="blue-text">EXAMPLE:</span> Amp		\|<span class="blue-text">EXAMPLE:</span> Amp
	\|<span class="blue-text">EXAMPLE:</span>17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]		\|<span class="blue-text">EXAMPLE:</span>
	\|<span class="blue-text">EXAMPLE:</span>''ERBB2''		17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
			\|<span class="blue-text">EXAMPLE:</span>
			''ERBB2''
	\|<span class="blue-text">EXAMPLE:</span> D, P, T		\|<span class="blue-text">EXAMPLE:</span> D, P, T
	\|		\|
	\|<span class="blue-text">EXAMPLE:</span>Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.		\|<span class="blue-text">EXAMPLE:</span>
			Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
	\|-		\|-
	\|		\|
Line 177:		Line 188:
	\|		\|
	\|		\|
	\|}~~<br />~~		\|}
	==Characteristic Chromosomal or Other Global Mutational Patterns==		==Characteristic Chromosomal or Other Global Mutational Patterns==